Alzamend Neuro (ALZN)

• Market cap: $6.03M
• 1 day: -11.20%
• 5 days: -6.72%
• 1 month: -15.27%
• 3 months: -34.32%
• 6 months: -72.18%
• Year to date: -87.93%
• 1 year: -86.82%
• 5 years: -99.95%
• 10 years: -99.95%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Employees: 7

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3.74% less ownership

Funds ownership: 4.82% [Q2] → 1.08% (-3.74%) [Q3]

25% less funds holding

Funds holding: 16 [Q2] → 12 (-4) [Q3]

53% less capital invested

Capital invested by funds: $150K [Q2] → $71.2K (-$79.3K) [Q3]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

88% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 8

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $32 2,783% upside
• Avg. target: $32 2,783% upside
• High target: $32 2,783% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Edward Woo 38% 1-year accuracy 28 / 73 met price target

2,783% upside $32

Buy Maintained

16 Dec 2024